MOESM2 of Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients

MLA

Gui-Qi Zhu, et al. MOESM2 of Development and Validation of a New Tumor-Based Gene Signature Predicting Prognosis of HBV/HCV-Included Resected Hepatocellular Carcinoma Patients. Jan. 2019. EBSCOhost, https://doi.org/10.6084/m9.figshare.8294180.v1.

APA

Gui-Qi Zhu, Yang, Y., Er-Bao Chen, Wang, B., Xiao, K., Shi, S.-M., Zhou, Z.-J., Shao-Lai Zhou, Wang, Z., Shi, Y.-H., Fan, J., Zhou, J., Liu, T.-S., & Dai, Z. (2019). MOESM2 of Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. https://doi.org/10.6084/m9.figshare.8294180.v1

Chicago

Gui-Qi Zhu, Yi Yang, Er-Bao Chen, Biao Wang, Kun Xiao, Shi-Ming Shi, Zheng-Jun Zhou, et al. 2019. “MOESM2 of Development and Validation of a New Tumor-Based Gene Signature Predicting Prognosis of HBV/HCV-Included Resected Hepatocellular Carcinoma Patients,” January. doi:10.6084/m9.figshare.8294180.v1.